September #147 : Hep C Drug to the Rescue? - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

The Castaways

Undress for Success




Stomaching Nausea

No Behind Left Behind

Hep C Drug to the Rescue?

Garlic Pill Warning

Mexicanos y HIV

Can Hypnosis Tame PN Pain?

Getting Out and Staying Healthy

Throwing the Book at Marijuana

Kidney News

Tribal Council

The Good Germs




Wedding Crashers

Running on Empty

The Freshman

Red-Carpet Ready

POZ / NEG

Please Do Stop His Music

The Incredible Bulk

M·A·C Attack

Birthday Girls




Editor's Letter-September 2008

Mailbox-September 2008

The NAPWA/TAEP HIV/AIDS Policy Report

GMHC Treatment Issues-September 2008



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

September 2008


Hep C Drug to the Rescue?

by Laura Whitehorn

Hepatitis C (HCV), the liver-damaging virus that affects about 33 percent of HIV-positive people, is tough to treat. The standard therapy (Pegasys plus ribavirin) takes about a year, works in only about a third of those with HIV and often causes unpleasant side effects. So, for some time now, newer classes of hepatitis meds have been badly needed. Good news: A  front-runner in the development pipeline, telaprevir—a protease inhibitor for HCV—is steadily advancing.

In a recent Phase II trial, 65 percent of participants who added telaprevir to the standard hep C drugs for the first 12 weeks of treatment cleared HCV; only 45 percent of those taking just the standard drugs did. A bonus: In the telaprevir group, treatment time was cut from 12 months to six.

But there’s a catch. To date, telaprevir trials have excluded people with HIV. Theoretically, if approved,  “telaprevir should increase cure rates for coinfected people,” says Daniel Raymond of the Harm Reduction Coalition, “though I doubt it will shorten the duration of their treatment.”

Hey, why not include HIV positive people in trials and find out?

Search: HCV, hepatitis C


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         

[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    fokisi
    Long Beach
    California


    slimcuteguy
    Asheville
    North Carolina


    usuallyhappy
    Palm Springs
    California


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.